[
  {
    "ts": "2026-01-11T03:11:24+00:00",
    "headline": "What adidas (XTRA:ADS)'s Rare Bank of America Sell Rating Says About Its Competitive Moat",
    "summary": "In early January 2026, Bank of America issued a rare sell rating on adidas, citing slowing growth and intensifying competition from brands such as Nike, On, Asics, and Puma. The downgrade underscores how shifting casualwear trends and a crowded performance footwear market are testing adidas’ ability to defend its brand position. Next, we’ll examine how Bank of America’s concerns about mounting competition could influence adidas’ existing investment narrative and outlook. Outshine the giants:...",
    "url": "https://finance.yahoo.com/news/adidas-xtra-ads-rare-bank-031124571.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a535fea4-677b-3fb6-852c-91d5ef891615",
      "content": {
        "id": "a535fea4-677b-3fb6-852c-91d5ef891615",
        "contentType": "STORY",
        "title": "What adidas (XTRA:ADS)'s Rare Bank of America Sell Rating Says About Its Competitive Moat",
        "description": "",
        "summary": "In early January 2026, Bank of America issued a rare sell rating on adidas, citing slowing growth and intensifying competition from brands such as Nike, On, Asics, and Puma. The downgrade underscores how shifting casualwear trends and a crowded performance footwear market are testing adidas’ ability to defend its brand position. Next, we’ll examine how Bank of America’s concerns about mounting competition could influence adidas’ existing investment narrative and outlook. Outshine the giants:...",
        "pubDate": "2026-01-11T03:11:24Z",
        "displayTime": "2026-01-11T03:11:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/cb577674b7e557d971f138507100a6d5",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5FuWnDACU..5OK.AroKx5g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/cb577674b7e557d971f138507100a6d5.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K2z4xhhhuqblfIvoH2uQcA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/cb577674b7e557d971f138507100a6d5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/adidas-xtra-ads-rare-bank-031124571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adidas-xtra-ads-rare-bank-031124571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAC"
            },
            {
              "symbol": "ADDDF"
            },
            {
              "symbol": "ADDYY"
            },
            {
              "symbol": "NKE"
            },
            {
              "symbol": "ASCCF"
            },
            {
              "symbol": "PMMAF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-11T05:10:20+00:00",
    "headline": "The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight",
    "summary": "BofA Securities recently initiated coverage on Amphastar Pharmaceuticals with a hold rating and a US$30 target, while the company’s leadership also presented at the J.P. Morgan 2026 Healthcare Conference, highlighting its portfolio of generic and proprietary injectable, inhalation, and intranasal products. Together, the fresh analyst coverage and conference appearance have drawn new attention to Amphastar’s investment in capacity expansion and its proprietary product pipeline. With BofA’s...",
    "url": "https://finance.yahoo.com/news/bull-case-amphastar-pharmaceuticals-amph-051020077.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "19796c58-d41c-30c4-828b-a07c0d1528d7",
      "content": {
        "id": "19796c58-d41c-30c4-828b-a07c0d1528d7",
        "contentType": "STORY",
        "title": "The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight",
        "description": "",
        "summary": "BofA Securities recently initiated coverage on Amphastar Pharmaceuticals with a hold rating and a US$30 target, while the company’s leadership also presented at the J.P. Morgan 2026 Healthcare Conference, highlighting its portfolio of generic and proprietary injectable, inhalation, and intranasal products. Together, the fresh analyst coverage and conference appearance have drawn new attention to Amphastar’s investment in capacity expansion and its proprietary product pipeline. With BofA’s...",
        "pubDate": "2026-01-11T05:10:20Z",
        "displayTime": "2026-01-11T05:10:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-amphastar-pharmaceuticals-amph-051020077.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-amphastar-pharmaceuticals-amph-051020077.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMPH"
            },
            {
              "symbol": "BAC"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-11T06:05:58+00:00",
    "headline": "BofA Keeps Neutral Rating on Lumentum Holdings Inc. (LITE)",
    "summary": "Lumentum Holdings Inc. (NASDAQ:LITE) is among the 20 Best Performing Stocks in 2025. In mid-December, Wall Street firms raised their price targets for the company on multiple occasions. TheFly on December 16, 2025, reported that BofA kept its Neutral rating while increasing its price target for the corporation from $210 to $375. The firm stated […]",
    "url": "https://finance.yahoo.com/news/bofa-keeps-neutral-rating-lumentum-060558782.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "521af6fd-c288-3ae4-ab17-8cf0cc0c980c",
      "content": {
        "id": "521af6fd-c288-3ae4-ab17-8cf0cc0c980c",
        "contentType": "STORY",
        "title": "BofA Keeps Neutral Rating on Lumentum Holdings Inc. (LITE)",
        "description": "",
        "summary": "Lumentum Holdings Inc. (NASDAQ:LITE) is among the 20 Best Performing Stocks in 2025. In mid-December, Wall Street firms raised their price targets for the company on multiple occasions. TheFly on December 16, 2025, reported that BofA kept its Neutral rating while increasing its price target for the corporation from $210 to $375. The firm stated […]",
        "pubDate": "2026-01-11T06:05:58Z",
        "displayTime": "2026-01-11T06:05:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b8e04e2a9e32a03229ac492c6aebf91",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "BofA Keeps Neutral Rating On Lumentum Holdings Inc. (LITE)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Sb8XVrOY14bKVzUtqGo98g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b8e04e2a9e32a03229ac492c6aebf91.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nhLG8PrAvjIfzp84ew9IvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b8e04e2a9e32a03229ac492c6aebf91.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-keeps-neutral-rating-lumentum-060558782.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-keeps-neutral-rating-lumentum-060558782.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAC"
            },
            {
              "symbol": "LITE"
            },
            {
              "symbol": "COHR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]